Download MendeleyStructural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2.
Nguyen, Y.T.K., Chen, F., Giang, E., Saha, S., Ueno, L.A., Chen, C., Watson, C.T., Tzarum, N., Wilson, I.A., Law, M., Stanfield, R.L.(2026) NPJ Vaccines
- PubMed: 42009696 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41541-026-01449-1
- Primary Citation Related Structures:
9MNQ, 9MNS, 9MNT, 9MNU, 9MRZ, 9MS9, 9MSC - PubMed Abstract:
Hepatitis C continues to be a significant public health problem despite advancements in antiviral therapeutics. To eliminate this disease, an effective vaccine against new infections and re-infections is needed. However, to date only one Hepatitis C virus (HCV) envelope protein (E1E2) immunogen, developed by Chiron Inc., has been tested in a Phase I clinical trial (ClinicalTrials.gov identifier NCT00500747). To establish a benchmark for elicitation of broadly neutralizing antibodies (bnAbs) by E1E2, we previously immunized non-human primates (NHPs) with this immunogen and isolated monoclonal nAbs that exhibit neutralization potency comparable to human nAbs. Here we show that NHP nAbs, encoded by germline genes IGHV1-138*01 and IGHV4-NL_5*01 (homologs of human IGHV1-69*10 and IGHV4-59*12, respectively), recognize a relatively conserved E2 region (neutralizing face) proximal to antigenic region 3 (AR3). These NHP AR3-targeting nAbs share highly similar binding modes to human AR3-targeting nAbs, suggesting a similarity in human and NHP immune responses to the same HCV immunogen.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Organizational Affiliation:
